Grant: CIHR Fellowship
Université de Montréal
$90,000.00
A systems-level study of the mechanisms leading to RAF dimerization and activation
EF 2011-12
Résumé
Hyperactivation of RAS/ERK signaling is among the key events leading to tumor initiation and progression. Signaling within this pathway requires the proper assembly of three core kinases (RAF, MEK and ERK) that convey incoming signals by the means of a phosphorylation cascade. Of all kinases, RAF (particularly BRAF) is the most frequently mutated in various types of human cancers. Recent work has shown that RAF activation requires the essential homo or heterodimerization of its kinase domain with other RAF paralogs (ARAF, BRAF or CRAF) or with KSR family members (KSR1 or KSR2). The RAF kinase domain dimerization surface was mapped at IRIC by Dr. Marc Therrien and has recently been implicated in adverse and paradoxical effects of RAF inhibitors used in clinical studies. These findings make RAF dimerization a logical target for identification and development of new cancer therapies. We have recently developed a bioluminescence resonance energy transfer (BRET) assay to study RAF family members interactions. We want to use this assay to define the spectrum of RAF/RAF interactions in live human cells. We will determine the impact of upstream (RAS) pathway components on the formation of RAF dimers. Finally, we will conduct a RNA interference screen to identify novel regulators of RAF dimerization. We expect that this research program will allow determining what configurations of the RAF/RAF dimer are important for cancer signaling. This research program will lead to a better understanding of the mechanism of RAF activation and this will eventually translate into better anti-cancer therapies.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
256051
Name
Lavoie Hugo
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
A systems-level study of the mechanisms leading to RAF dimerization and activation
Programtype2
Fellowship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$90,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Bioluminescence; Cancer Therapies; Fluorescence; High-Throughput Screening; Molecular Biology; Pharmacology; Protein-Protein Interactions
Abstract
Hyperactivation of RAS/ERK signaling is among the key events leading to tumor initiation and progression. Signaling within this pathway requires the proper assembly of three core kinases (RAF, MEK and ERK) that convey incoming signals by the means of a phosphorylation cascade. Of all kinases, RAF (particularly BRAF) is the most frequently mutated in various types of human cancers. Recent work has shown that RAF activation requires the essential homo or heterodimerization of its kinase domain with other RAF paralogs (ARAF, BRAF or CRAF) or with KSR family members (KSR1 or KSR2). The RAF kinase domain dimerization surface was mapped at IRIC by Dr. Marc Therrien and has recently been implicated in adverse and paradoxical effects of RAF inhibitors used in clinical studies. These findings make RAF dimerization a logical target for identification and development of new cancer therapies. We have recently developed a bioluminescence resonance energy transfer (BRET) assay to study RAF family members interactions. We want to use this assay to define the spectrum of RAF/RAF interactions in live human cells. We will determine the impact of upstream (RAS) pathway components on the formation of RAF dimers. Finally, we will conduct a RNA interference screen to identify novel regulators of RAF dimerization. We expect that this research program will allow determining what configurations of the RAF/RAF dimer are important for cancer signaling. This research program will lead to a better understanding of the mechanism of RAF activation and this will eventually translate into better anti-cancer therapies.
Competitiondate
201202
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Lavoie, Hugo
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $90,000~ $0~